References
- Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 4th edn. (Text Revision). Washington, DC: American Psychiatric Association, 2000
- Drake C, Kryger M, Phillips B. National Sleep Foundation Survey 2005. Washington, DC: The National Sleep Foundation, 2005
- Berman T, Nino-Murcia G, Roehrs T. Sleep disorders: take them seriously. Patient Care 1990;24:85-112
- Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone 2003;5:5-15
- Takeda Pharmaceuticals North America. Rozerem [package insert]. Deerfield, IL, USA, 2005
- Gottesmann C. GABA mechanisms and sleep. Neuroscience 2002;111:231-9
- Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005;48:301-10
- Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006;63:1149-57
- Barrett P, Conway S, Morgan PJ. Digging deep: structure–function relationships in the melatonin receptor family. J Pineal Res 2003;35:221-30
- Dubocovich ML. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med 2007;8(Suppl 3):34-42
- Liu C, Weaver DR, Jin X, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997;19:91-102
- Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24
- Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005;28:303-7
- Roth T, Seiden D, Wang-Weigand S, et al. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23:1005-14
- Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7:312-18
- Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3:495-504
- Zammit G, Schwartz H, Roth T, et al. The effects of ramelteon in a first-night model of transient insomnia. Sleep Med 2009;10:55-9. Epub Aug 8, 2008
- Mayer G, Wang-Weigand S, Roth-Schechter B, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic, primary insomnia. Sleep 2009;32:351–360
- Rosner B. Fundamental of Biostatistics, 6th edn. Pacific Grove, CA: Duxbury Press, 2006
- Crestani F, Martin JR, Mohler H, et al. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 2000;131:1251-4
- Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984;230:94-102
- Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007;22:1335-50
- McCall WV, D’Agostino Jr R, Dunn A. A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med 2003;4:57-62
- Miller FG, Rosenstein DL. The nature and power of the placebo effect. J Clin Epidemiol 2006;59:331-5
- Morin CM, Wooten V. Psychological and pharmacological approaches to treating insomnia: critical issues in assessing their separate and combined effects. Clin Psychol Rev 1996;16:521-42